Newer therapies will steer type 2 diabetes market in South-East Asia to $2.7 billion by 2022
![](/46/pdcnewsitem/04/20/83/GBI%20Research.png)
Increase will be driven by the growing use of recently approved and emerging branded T2DM therapeutics, in favour of lower-cost generic products, says GBI Research.
The South-East Asian Type 2 Diabetes Mellitus (T2DM) market, which includes South Korea, Singapore, Taiwan, Malaysia, the Philippines, Thailand, Vietnam and Indonesia, will rise from $1.7 billion in 2015 to $2.7 billion by 2022, at a compound annual growth rate of 7.1%, according to business intelligence provider GBI Research.
The company’s latest report, 'Type 2 Diabetes Mellitus Therapeutics in South-East Asia Markets to 2022 – Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth' states that as well as the rapidly expanding prevalence population in South-East Asia, market growth will be driven by the increased uptake of recently approved and emerging branded T2DM therapeutics, in favor of lower-cost generic products.
Aswini Nath, Analyst for GBI Research, explains: “Unmet needs relating to patient convenience and ease of use will be addressed significantly over the forecast period. Higher levels of innovation are apparent in the early-stage pipeline, which may lead to considerable improvements beyond the existing range of products, in terms of safety and efficacy in the long term.
“In terms of recently approved therapeutics, GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors have already achieved strong market uptake and are all expected to increase their market shares over the forecast period. In comparison with many previously marketed therapies, these new products provide improved weight control and lowered hypoglycemia risk.”
In terms of late-stage pipeline products with the potential to change the treatment paradigm, six candidates stand out as offering superior safety, efficacy, and patient compliance. These are Novo Nordisk’s NN-9535 (semaglutide subcutaneous formulation) and OG-217SC (semaglutide oral formulation) and Eli Lilly’s Trulicity (dulaglutide), which are GLP-1 receptor agonists; Merck’s ertugliflozin and Theracos's bexagliflozin, which are SGLT-2 inhibitors; and Merck’s omarigliptin, which is a DPP-4 inhibitor.
Of these products, GBI Research believes that OG-217SC, being a first-to-market oral formulation in the GLP-1 agonist class of drug, has the most potential to change the treatment paradigm due to its improved administration route compared to other drugs in the same class.
However, Nath adds: “Although increased uptake of branded drugs is expected, metformin – a low-cost generic drug – will maintain its pivotal role in the T2DM treatment algorithm in South-East Asia. Due to its well-characterized safety and efficacy profiles, wide availability and low cost, metformin will continue to be prescribed as the first-line pharmacotherapy and also remain the favored option for use in combination therapies.”
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance